glp-1 receptor agonists for type 2 diabetes Explained Pharmacy & Medical Students: Mechanism, Uses, and Side Effects New Developments in Pharmacological Treatment

doi: 10.1007/s11596-020-2281-2 [DOI] [PubMed] [Google Scholar] 40

A robust pipeline of entero-pancreatic hormone-based therapies is currently in development, with several dual and triple agonists expected to emerge for obesity in the coming years

While its taken years and my trajectory has not been perfect, the overall composition of my body keeps improving: Ive been steadily increasing muscle mass while decreasing body fat

2012;7(2):e32008

Survodutide is also being studied in Phase 3 trials for the treatment of MASH

[207].Oramed Pharmaceuticals, Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus